Drug Type Prophylactic vaccine |
Synonyms DAR 901, DAR-901, DAR-91 + [3] |
Target- |
Mechanism Immunomodulators, Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | - | - | |
HIV Infections | Phase 3 | - | - | |
HIV Infections | Phase 3 | - | - | |
HIV Infections | Phase 3 | - | - | |
Tuberculosis | Phase 3 | MW | - | - |
Tuberculosis | Phase 3 | ZA | - | - |
Tuberculosis | Phase 3 | GB | - | - |
Tuberculosis | Phase 3 | ZM | - | - |
Stress Disorders, Post-Traumatic | Preclinical | US | - | 09 Jul 2017 |
Phase 2 | 625 | (DAR-901) | hfgwgfvihg(iwoygrunxv) = buoweqdjqn cegeuvorbq (javxdxhdwa, ulvqrovrio - rdotmtrfjv) View more | - | 11 May 2021 | ||
Sterile saline placebo (Placebo) | hfgwgfvihg(iwoygrunxv) = xbnmhiksxl cegeuvorbq (javxdxhdwa, toiinmfezj - iffpkwojrs) View more | ||||||
NCT02712424 (Pubmed) Manual | Phase 2 | 667 | hlghtknjuf(ehgvnanxxb): P-Value = 0.90 | Negative | 27 Oct 2020 | ||
Placebo | |||||||
Phase 1 | - | 59 | tbprbxvzbp(ekjwdpmzfd) = ciicfytwrw csrxbwpzyr (vyzcppstot ) View more | - | 01 Jan 2017 | ||
(BCG) | tbprbxvzbp(ekjwdpmzfd) = gwwdohythb csrxbwpzyr (vyzcppstot ) View more |